Key facts
- It has raised $250K; the latest was Seed Round ($140K) in Mar 2025.
- Notable investors include Right Side Capital Management, Forum Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Revilico
- ·The full record, as it builds
Funding rounds
No funding rounds for Revilico are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Revilico
Developer of an AI-driven drug discovery platform intended to accelerate and optimize the development of new therapeutics. The company's platform offers AI-powered tools for target identification, compound screening and lead optimization, delivering significant reductions in drug discovery time and costs, enabling customers to efficiently identify promising drug candidates.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2024
- Employees
- 11
- Website
- revilico.bio/
- Ownership
- Privately Held (backing)
Revilico doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Revilico shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Revilico in its N-PORT filings yet. We sweep new filings monthly.